Royalty Pharma PLC (NASDAQ:RPRX) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. raised its position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 51.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 113,718 shares of the biopharmaceutical company's stock after buying an additional 38,650 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Royalty Pharma were worth $3,567,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nissay Asset Management Corp Japan ADV increased its holdings in shares of Royalty Pharma by 0.7% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock valued at $1,238,000 after acquiring an additional 349 shares during the period. National Bank of Canada FI grew its position in Royalty Pharma by 21.8% during the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 371 shares during the last quarter. Sherbrooke Park Advisers LLC increased its stake in Royalty Pharma by 1.1% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company's stock valued at $890,000 after purchasing an additional 380 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in Royalty Pharma by 76.4% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 414 shares during the period. Finally, Arizona State Retirement System raised its stake in shares of Royalty Pharma by 0.5% during the fourth quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company's stock worth $2,822,000 after purchasing an additional 537 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock traded up $0.14 during trading on Friday, reaching $36.33. The company's stock had a trading volume of 1,196,661 shares, compared to its average volume of 3,679,527. The business has a 50 day moving average price of $33.88 and a 200-day moving average price of $31.98. Royalty Pharma PLC has a 12-month low of $24.05 and a 12-month high of $36.43. The company has a market capitalization of $20.42 billion, a P/E ratio of 19.64, a price-to-earnings-growth ratio of 1.87 and a beta of 0.50. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.68.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.99 by $0.07. The business had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a return on equity of 24.71% and a net margin of 48.23%. As a group, sell-side analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were paid a dividend of $0.22 per share. The ex-dividend date was Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.42%. Royalty Pharma's dividend payout ratio (DPR) is 47.57%.

Wall Street Analysts Forecast Growth

RPRX has been the topic of several recent research reports. Wall Street Zen cut shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. Finally, Morgan Stanley assumed coverage on shares of Royalty Pharma in a research note on Friday, May 16th. They set an "overweight" rating and a $51.00 price target on the stock. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Royalty Pharma has an average rating of "Buy" and a consensus target price of $47.33.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.